A5070778939- Pharmacogenetics and Drug Metabolism
- Computational Drug Discovery Methods
- Amino Acid Enzymes and Metabolism
- Chemical Reactions and Isotopes
- Statistical Methods in Clinical Trials
- Monoclonal and Polyclonal Antibodies Research
Sanofi (France)
2015-2023
Janssen (United States)
2017
Eli Lilly (United States)
2017
Boehringer Ingelheim (United States)
2017
Vertex Pharmaceuticals (United States)
2017
Pfizer (United States)
2017
Amgen (United States)
2017
Corning (United States)
2017
Sekisui XenoTech (United States)
2017
Ono Pharmaceutical (United States)
2017
The European Medicines Agency (EMA), the Pharmaceutical and Medical Devices (PMDA), Food Drug Administration (FDA) have issued guidelines for conduct of drug-drug interaction studies. To examine applicability these regulatory recommendations specifically induction, a group scientists, under auspices Metabolism Leadership Group Innovation Quality (IQ) Consortium, formed Induction Working (IWG). A team 19 from 16 39 pharmaceutical companies that are members IQ Consortium two Contract Research...
Tusamitamab ravtansine is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody (IgG1) and DM4 payload. Even if its main metabolite methyl-DM4 (Me-DM4) circulate at low concentrations after ADC administration, their potential as perpetrators cytochrome P450 mediated drug-drug interaction was assessed. In vitro studies in human hepatocytes indicated that Me-DM4 elicited clear concentration-dependent down regulation enzymes (CYP3A4, 1A2, 2B6). Because unstable under the...